Bayer seeks European marketing authorization for investigational contrast agent, gadoquatrane: Berlin Friday, July 11, 2025, 11:00 Hrs [IST] Bayer announced the submission of a ma ...

Two new open-source tools are set to make fluorescence lifetime imaging microscopy—or FLIM—faster, simpler and more ...

Photoacoustic tomography (PAT) market is transitioning to the next era: The Innovation-driven growth phase. Owing to the worldwide PAT market is anticipated to expand at a sizable CAGR throughout the ...

On the other hand, it is in the past decade that coherent phase contrast imaging methods for STEM have begun to show their potential. Annular bright field (ABF) imaging, first suggested by H. Rose, ...

The Global Digital Holographic Microscopy Market is expected to reach at a CAGR of 20.4% during the forecast period 2025-2033. The Digital Holographic Microscopy Market is expanding due to rising ...

Differential phase contrast imaging with a grating interferometer is a promising new radiographic technique providing three distinct contrast mechanisms-absorption, phase, and scatter (or dark ...

About gadoquatrane Gadoquatrane is Bayer’s investigational extracellular macrocyclic contrast agent in clinical development for contrast enhancement in MRI.

Given its capability of achieving pixel super-resolution, twin-image elimination, and large-SBP phase reconstruction, the MPPN-PSR method provides high-throughput phase imaging with high accuracy.

Results of the Phase I clinical trial, presented at the bi-annual Contrast Media Research symposium in Oslo, Norway, conclude that this novel macrocyclic manganese-based contrast agent was well ...

In parallel, X-ray phase-contrast imaging is becoming more widely available and gaining attention for both pre-clinical and clinical applications. Phase-contrast techniques, many of which can produce ...